Cargando…

Abiraterone induces SLCO1B3 expression in prostate cancer via microRNA-579-3p

Understanding mechanisms of resistance to abiraterone, one of the primary drugs approved for the treatment of castration resistant prostate cancer, remains a priority. The organic anion polypeptide 1B3 (OATP1B3, encoded by SLCO1B3) transporter has been shown to transport androgens into prostate canc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Barbier, Roberto H., McCrea, Edel M., Lee, Kristi Y., Strope, Jonathan D., Risdon, Emily N., Price, Douglas K., Chau, Cindy H., Figg, William D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8144422/ https://www.ncbi.nlm.nih.gov/pubmed/34031488 http://dx.doi.org/10.1038/s41598-021-90143-4

Ejemplares similares

THU579 Severe Hypokalemia: Is It Mineralocorticoid Excess Induced By Abiraterone Or Exogenous Hypercortisolism?
por: Katwal, Dilasha, et al.
Publicado: (2023)

Are sex discordant outcomes in COVID-19 related to sex hormones?
por: Strope, Jonathan D., et al.
Publicado: (2020)

Precision medicine applications in prostate cancer
por: McCrea, Edel M., et al.
Publicado: (2018)

TMPRSS2: Potential Biomarker for COVID‐19 Outcomes
por: Strope, Jonathan D., et al.
Publicado: (2020)

Drugging the undruggable: activity-based protein profiling offers opportunities for targeting the KLK activome
por: Lee, Kristi Y., et al.
Publicado: (2022)

MicroRNA-579-3p Exerts Neuroprotective Effects Against Ischemic Stroke via Anti-Inflammation and Anti-Apoptosis
por: Jia, Jiaoying, et al.
Publicado: (2020)

SLCO1A2, SLCO1B1 and SLCO2B1 polymorphisms influences chloroquine and primaquine treatment in Plasmodium vivax malaria
por: Sortica, Vinicius A, et al.
Publicado: (2017)

579. Clinical and Drug Resistance Characteristics of Providencia spp. Infections
por: Kale-Pradhan, Pramodini, et al.
Publicado: (2023)

Effects of SLCO1B1 and SLCO1B3 Genetic Polymorphisms on Valsartan Pharmacokinetics in Healthy Korean Volunteers
por: Song, Gonjin, et al.
Publicado: (2021)

Loss of SLCO1B3 drives taxane resistance in prostate cancer
por: de Morrée, Ellen S, et al.
Publicado: (2016)

Suppression of PtrDUF579-3 Expression Causes Structural Changes of the Glucuronoxylan in Populus
por: Song, Dongliang, et al.
Publicado: (2016)

MicroRNA-579-3p Exerts Neuroprotective Effects Against Ischemic Stroke via Anti-Inflammation and Anti-Apoptosis [Retraction]
Publicado: (2021)

Challenges to improved therapeutics for metastatic castrate resistant prostate cancer: from recent successes and failures
por: Huang, Xuan, et al.
Publicado: (2012)

Targeting the metastatic niche: Single-cell lineage tracing in prime time
por: Sommer, Elijah R., et al.
Publicado: (2023)

Association of the DNMT3B -579G>T Polymorphism with Risk of Thymomas in Patients with Myasthenia Gravis
por: Coppedè, Fabio, et al.
Publicado: (2013)

Photochemistry and Photophysics of Cholesta-5,7,9(11)-trien-3β-ol in Ethanol
por: Saltiel, Jack, et al.
Publicado: (2023)

Correction to Lancet Psychiatry 2021; 8: 579–88
Publicado: (2021)

SAT-579 Experiences with Hypertriglyceridemic Pancreatitis: A Mini Case Series
por: Majety, Priyanka, et al.
Publicado: (2020)

The Emerging Role of the SLCO1B3 Protein in Cancer Resistance
por: Sun, Ruipu, et al.
Publicado: (2020)

Phosphorylation of FE65 at threonine 579 by GSK3β stimulates amyloid precursor protein processing
por: Lee, Yat Shing, et al.
Publicado: (2017)

Investigation of the DNMT3B –579 G>T Promoter Polymorphism in Patients with Colorectal Cancer in an Azerbaijani Population
por: Bayramov, Bayram, et al.
Publicado: (2022)

SLCO1B3 promotes colorectal cancer tumorigenesis and metastasis through STAT3
por: Zhi, Lianghui, et al.
Publicado: (2021)

Association Study of SLCO1B3 and ABCC3 Genetic Variants in Gallstone Disease
por: Banach, Bolesław, et al.
Publicado: (2022)

Abiraterone Acetate
Publicado: (2012)

MON-579 Toxic Multinodular Goiter And Thyroid Cancer Risk
por: Kampe-Okotie, Doris, et al.
Publicado: (2019)

Germline Genetics of Prostate Cancer: Prevalence of Risk Variants and Clinical Implications for Disease Management
por: Doan, David K., et al.
Publicado: (2021)

Hunger modulates perceptions of food health but not taste in restricted eaters
por: Herrero, Lucia, et al.
Publicado: (2023)

Examining HSD3B1 as a possible biomarker to detect prostate cancer patients who are likely to progress on ADT
por: Handy, Whitney F., et al.
Publicado: (2020)

Two members of the DUF579 family are responsible for arabinogalactan methylation in Arabidopsis
por: Temple, Henry, et al.
Publicado: (2019)

Truncation of type IV pilin induces mucoidy in Pseudomonas aeruginosa strain PAO579
por: Ryan Withers, T, et al.
Publicado: (2013)

Single whole genome sequencing analysis blazes the trail for precision medicine
por: Napoli, Giulia C., et al.
Publicado: (2022)

Functional Drug Screening in the Era of Precision Medicine
por: Napoli, Giulia C., et al.
Publicado: (2022)

miR‐579‐3p Controls Hepatocellular Carcinoma Formation by Regulating the Phosphoinositide 3‐Kinase–Protein Kinase B Pathway in Chronically Inflamed Liver
por: Quintavalle, Cristina, et al.
Publicado: (2022)

Low cost abiraterone
por: Barreiro, Diego Martin, et al.
Publicado: (2015)

Abiraterone-Induced Endocrinopathies
por: Decamps, Scarlett, et al.
Publicado: (2023)

The DNMT3B -579G>T Polymorphism Is Significantly Associated With the Risk of Gastric Cancer but not Lung Cancer in Chinese Population
por: Chen, Bifeng, et al.
Publicado: (2017)

miR579-3p is an inhibitory modulator of neointimal hyperplasia and transcription factors c-MYB and KLF4
por: Xie, Xiujie, et al.
Publicado: (2023)

Pharmacogenomic-guided clozapine administration based on HLA-DQB1, HLA-B and SLCO1B3-SLCO1B7 variants: an effectiveness and cost-effectiveness analysis
por: Ninomiya, Kohei, et al.
Publicado: (2022)

Pilot study of gadoxetate disodium-enhanced mri for localized and metastatic prostate cancers
por: Lochrin, Sarah E., et al.
Publicado: (2021)

Management of prostate cancer by targeting 3βHSD1 after enzalutamide and abiraterone treatment
por: Mei, Zejie, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_knm2kf5kovdi66t2dg50n4g46o